Furthermore, this study does not compare the efficacy and safety of elocalcitol with newer anti-obesity agents, such as GLP-1 receptor agonists (e.g., semaglutide) or dual GLP-1/GIP agonists (e.g., tirzepatide), which are widely used and administered weekly via parenteral routes. The gene discussed is GIP; the disease is obesity disorder.